Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models.

Wengner AM, Siemeister G, Lücking U, Lefranc J, Wortmann L, Lienau P, Bader B, Bömer U, Moosmayer D, Eberspächer U, Golfier S, Schatz CA, Baumgart SJ, Haendler B, Lejeune P, Schlicker A, von Nussbaum F, Brands M, Ziegelbauer K, Mumberg D.

Mol Cancer Ther. 2019 Oct 3. pii: molcanther.0019.2019. doi: 10.1158/1535-7163.MCT-19-0019. [Epub ahead of print]

PMID:
31582533
2.

Quantitative molecular tissue atlas of Bis(monoacylglycero)phosphate and phosphatidylglycerol membrane lipids in rodent organs generated by methylation assisted high resolution mass spectrometry.

Wang X, Schmitt MV, Xu L, Jiao Y, Guo L, Lienau P, Reichel A, Liu X.

Anal Chim Acta. 2019 Nov 25;1084:60-70. doi: 10.1016/j.aca.2019.07.060. Epub 2019 Jul 31.

PMID:
31519235
3.
4.

Exploration of Novel Chemical Space: Synthesis and in vitro Evaluation of N-Functionalized Tertiary Sulfonimidamides.

Izzo F, Schäfer M, Lienau P, Ganzer U, Stockman R, Lücking U.

Chemistry. 2018 Jul 2;24(37):9295-9304. doi: 10.1002/chem.201801557. Epub 2018 Jun 19.

5.

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.

Lücking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, Briem H, Terebesi I, Meyer K, Prelle K, Denner K, Bömer U, Schäfer M, Eis K, Valencia R, Ince S, von Nussbaum F, Mumberg D, Ziegelbauer K, Klebl B, Choidas A, Nussbaumer P, Baumann M, Schultz-Fademrecht C, Rühter G, Eickhoff J, Brands M.

ChemMedChem. 2017 Nov 8;12(21):1776-1793. doi: 10.1002/cmdc.201700447. Epub 2017 Oct 16.

6.

Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.

Narita T, Ishida T, Ito A, Masaki A, Kinoshita S, Suzuki S, Takino H, Yoshida T, Ri M, Kusumoto S, Komatsu H, Imada K, Tanaka Y, Takaori-Kondo A, Inagaki H, Scholz A, Lienau P, Kuroda T, Ueda R, Iida S.

Blood. 2017 Aug 31;130(9):1114-1124. doi: 10.1182/blood-2016-09-741983. Epub 2017 Jun 23.

PMID:
28646117
7.

BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity.

Santag S, Siegel F, Wengner AM, Lange C, Bömer U, Eis K, Pühler F, Lienau P, Bergemann L, Michels M, von Nussbaum F, Mumberg D, Petersen K.

Cancer Lett. 2017 Apr 1;390:21-29. doi: 10.1016/j.canlet.2016.12.029. Epub 2016 Dec 31.

8.

Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9.

Ayaz P, Andres D, Kwiatkowski DA, Kolbe CC, Lienau P, Siemeister G, Lücking U, Stegmann CM.

ACS Chem Biol. 2016 Jun 17;11(6):1710-9. doi: 10.1021/acschembio.6b00074. Epub 2016 Apr 19.

9.

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.

Wengner AM, Siemeister G, Koppitz M, Schulze V, Kosemund D, Klar U, Stoeckigt D, Neuhaus R, Lienau P, Bader B, Prechtl S, Raschke M, Frisk AL, von Ahsen O, Michels M, Kreft B, von Nussbaum F, Brands M, Mumberg D, Ziegelbauer K.

Mol Cancer Ther. 2016 Apr;15(4):583-92. doi: 10.1158/1535-7163.MCT-15-0500. Epub 2016 Feb 1.

10.

Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.

Reichel A, Lienau P.

Handb Exp Pharmacol. 2016;232:235-60. doi: 10.1007/164_2015_26. Review.

PMID:
26330260
11.

Characterization of novel MPS1 inhibitors with preclinical anticancer activity.

Jemaà M, Galluzzi L, Kepp O, Senovilla L, Brands M, Boemer U, Koppitz M, Lienau P, Prechtl S, Schulze V, Siemeister G, Wengner AM, Mumberg D, Ziegelbauer K, Abrieu A, Castedo M, Vitale I, Kroemer G.

Cell Death Differ. 2013 Nov;20(11):1532-45. doi: 10.1038/cdd.2013.105. Epub 2013 Aug 9.

12.

The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer.

Lücking U, Jautelat R, Krüger M, Brumby T, Lienau P, Schäfer M, Briem H, Schulze J, Hillisch A, Reichel A, Wengner AM, Siemeister G.

ChemMedChem. 2013 Jul;8(7):1067-85. doi: 10.1002/cmdc.201300096. Epub 2013 May 13.

PMID:
23671017
13.

BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.

Siemeister G, Lücking U, Wengner AM, Lienau P, Steinke W, Schatz C, Mumberg D, Ziegelbauer K.

Mol Cancer Ther. 2012 Oct;11(10):2265-73. doi: 10.1158/1535-7163.MCT-12-0286. Epub 2012 Jul 19.

14.

Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values.

Krippendorff BF, Neuhaus R, Lienau P, Reichel A, Huisinga W.

J Biomol Screen. 2009 Sep;14(8):913-23. doi: 10.1177/1087057109336751. Epub 2009 Aug 12.

PMID:
19675314
15.

Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.

Hoffmann J, Fichtner I, Lemm M, Lienau P, Hess-Stumpp H, Rotgeri A, Hofmann B, Klar U.

Neuro Oncol. 2009 Apr;11(2):158-66. doi: 10.1215/15228517-2008-072. Epub 2008 Sep 9.

16.

A probabilistic approach to classifying metabolic stability.

Schwaighofer A, Schroeter T, Mika S, Hansen K, Ter Laak A, Lienau P, Reichel A, Heinrich N, Müller KR.

J Chem Inf Model. 2008 Apr;48(4):785-96. doi: 10.1021/ci700142c. Epub 2008 Mar 8.

PMID:
18327900
17.

Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities.

Lücking U, Siemeister G, Schäfer M, Briem H, Krüger M, Lienau P, Jautelat R.

ChemMedChem. 2007 Jan;2(1):63-77.

PMID:
17131463
18.

Optimizing classification of drug-drug interaction potential for CYP450 isoenzyme inhibition assays in early drug discovery.

Krippendorff BF, Lienau P, Reichel A, Huisinga W.

J Biomol Screen. 2007 Feb;12(1):92-9. Epub 2006 Nov 27.

PMID:
17130250

Supplemental Content

Loading ...
Support Center